These contain known cancer-testis antigen genes (MEGA5, MEGA1, TEX15, PNMA5 and ROR1) and a number of new candidate genes (PAX2, NTN4, NTNG2 and PDE10A), these genes can be used as tumour markers or potential therapeutic targets with some clinical value. Here, NTNG2 is linked to neoplasm.